MARKETSBiolinerx (blrx) stock soars on liver drug licensing agreementBy Annie PalmerSep 23, 2016 3:39 PM EDT
PRESS RELEASESBioLineRx Announces $4.39 Million Registered Direct OfferingBy PR NewswireJun 1, 2020 8:00 AM EDT
PRESS RELEASESBioLineRx Announces $9.0 Million Registered Direct OfferingBy PR NewswireMay 26, 2020 8:40 AM EDT
PRESS RELEASESBioLineRx To Report First Quarter 2020 Results On May 20, 2020By PR NewswireMay 15, 2020 7:00 AM EDT
PRESS RELEASESBioLineRx Announces Notice Of Allowance From USPTO For Patent Covering Motixafortide (BL-8040) In Combination With Anti-PD-1 For The Treatment Of Any Type Of CancerBy PR NewswireFeb 27, 2020 7:43 AM EST
PRESS RELEASESBioLineRx Completes Recruitment In Triple Combination Arm Of COMBAT/KEYNOTE-202 Study In Patients With Second-line Metastatic Pancreatic CancerBy PR NewswireJan 22, 2020 7:00 AM EST
PRESS RELEASESBioLineRx Receives Orphan Drug Designation For Motixafortide (BL-8040) For The Treatment Of Pancreatic Cancer In EuropeBy PR NewswireJan 14, 2020 7:00 AM EST
MARKETSBiolinerx (blrx) stock soars on liver drug licensing agreementBy Annie PalmerSep 23, 2016 3:39 PM EDT
OPINIONThese 7 stocks under $10 are making big moves to the upsideBy Roberto PedoneApr 15, 2016 7:59 AM EDT
MARKETSBioLineRx (BLRX) Stock Down on Negative Heart Disease Treatment ResultsBy Tony OwusuJul 27, 2015 10:49 AM EDT
MARKETSBioline RX (BLRX) Stock Gains on Positive Test Results, Coverage InitiationBy Tony OwusuJun 22, 2015 1:30 PM EDT
